$37.20
0.40% today
Nasdaq, Sep 23, 07:17 pm CET
ISIN
CA98420N1050
Symbol
XENE

Xenon Pharmaceuticals Inc. Target price 2025 - Analyst rating & recommendation

Xenon Pharmaceuticals Inc. Classifications & Recommendation:

Buy
96%
Hold
4%

Xenon Pharmaceuticals Inc. Price Target

Target Price $56.10
Price $37.35
Potential
Number of Estimates 18
18 Analysts have issued a price target Xenon Pharmaceuticals Inc. 2026 . The average Xenon Pharmaceuticals Inc. target price is $56.10. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 25 analysts: 24 Analysts recommend Xenon Pharmaceuticals Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Xenon Pharmaceuticals Inc. stock has an average upside potential 2026 of . Most analysts recommend the Xenon Pharmaceuticals Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 0.00 7.68

21 Analysts have issued a sales forecast Xenon Pharmaceuticals Inc. 2025 . The average Xenon Pharmaceuticals Inc. sales estimate is

$7.7m
Unlock
. This is
2.40% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$8.4m 12.00%
Unlock
, the lowest is
$7.4m 2.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $0.0
2026
$23.6m 207.88%
Unlock
2027
$102m 329.82%
Unlock
2028
$368m 261.83%
Unlock
2029
$726m 97.35%
Unlock
2030
$1.2b 58.88%
Unlock
2031
$1.3b 13.79%
Unlock
2032
$1.6b 25.69%
Unlock

6 Analysts have issued an Xenon Pharmaceuticals Inc. EBITDA forecast 2025. The average Xenon Pharmaceuticals Inc. EBITDA estimate is

$-340m
Unlock
. This is
7.60% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-317m 0.32%
Unlock
, the lowest is
$-364m 15.32%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-277m 30.54%
2025
$-340m 22.68%
Unlock
2026
$-401m 18.24%
Unlock
2027
$-345m 14.02%
Unlock
2028
$-276m 20.11%
Unlock
2029
$-45.0m 83.67%
Unlock

EBITDA Margin

2026
-1,697.71% 61.60%
Unlock
2027
-339.61% 80.00%
Unlock
2028
-74.99% 77.92%
Unlock
2029
-6.21% 91.72%
Unlock

21 Xenon Pharmaceuticals Inc. Analysts have issued a net profit forecast 2025. The average Xenon Pharmaceuticals Inc. net profit estimate is

$-330m
Unlock
. This is
18.59% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-311m 11.79%
Unlock
, the lowest is
$-349m 25.48%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-234m 28.48%
2025
$-330m 40.81%
Unlock
2026
$-362m 9.69%
Unlock
2027
$-353m 2.41%
Unlock
2028
$-279m 21.01%
Unlock
2029
$-55.6m 80.09%
Unlock
2030
$134m 341.12%
Unlock
2031
$313m 133.78%
Unlock
2032
$503m 60.69%
Unlock

Net Margin

2026
-1,530.69% 64.37%
Unlock
2027
-347.53% 77.30%
Unlock
2028
-75.86% 78.17%
Unlock
2029
-7.65% 89.92%
Unlock
2030
11.62% 251.90%
Unlock
2031
23.87% 105.42%
Unlock
2032
30.51% 27.82%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.01 -4.29
10.26% 42.52%
P/E negative
EV/Sales 297.85

21 Analysts have issued a Xenon Pharmaceuticals Inc. forecast for earnings per share. The average Xenon Pharmaceuticals Inc. EPS is

$-4.29
Unlock
. This is
21.19% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-4.04 14.12%
Unlock
, the lowest is
$-4.54 28.25%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.01 10.26%
2025
$-4.29 42.52%
Unlock
2026
$-4.70 9.56%
Unlock
2027
$-4.59 2.34%
Unlock
2028
$-3.63 20.92%
Unlock
2029
$-0.72 80.17%
Unlock
2030
$1.74 341.67%
Unlock
2031
$4.07 133.91%
Unlock
2032
$6.54 60.69%
Unlock

P/E ratio

Current -10.55 32.73%
2025
-8.71 17.45%
Unlock
2026
-7.94 8.84%
Unlock
2027
-8.14 2.52%
Unlock
2028
-10.30 26.54%
Unlock
2029
-51.73 402.23%
Unlock
2030
21.46 141.48%
Unlock
2031
9.18 57.22%
Unlock
2032
5.71 37.80%
Unlock

Based on analysts' sales estimates for 2025, the Xenon Pharmaceuticals Inc. stock is valued at an EV/Sales of

297.85
Unlock
and an P/S ratio of
361.33
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 305.00
2025
297.85 2.34%
Unlock
2026
96.74 67.52%
Unlock
2027
22.51 76.73%
Unlock
2028
6.22 72.36%
Unlock
2029
3.15 49.33%
Unlock
2030
1.98 37.06%
Unlock
2031
1.74 12.12%
Unlock
2032
1.39 20.44%
Unlock

P/S ratio

Current
2025
361.33 2.34%
Unlock
2026
117.36 67.52%
Unlock
2027
27.31 76.73%
Unlock
2028
7.55 72.36%
Unlock
2029
3.82 49.33%
Unlock
2030
2.41 37.06%
Unlock
2031
2.12 12.12%
Unlock
2032
1.68 20.43%
Unlock

Current Xenon Pharmaceuticals Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
RBC Capital
Locked
Locked
Locked Sep 02 2025
Wedbush
Locked
Locked
Locked Aug 12 2025
RBC Capital
Locked
Locked
Locked Aug 12 2025
Chardan Capital
Locked
Locked
Locked Aug 12 2025
Evercore ISI Group
Locked
Locked
Locked May 14 2025
Needham
Locked
Locked
Locked May 13 2025
HC Wainwright & Co.
Locked
Locked
Locked May 13 2025
Analyst Rating Date
Locked
RBC Capital:
Locked
Locked
Sep 02 2025
Locked
Wedbush:
Locked
Locked
Aug 12 2025
Locked
RBC Capital:
Locked
Locked
Aug 12 2025
Locked
Chardan Capital:
Locked
Locked
Aug 12 2025
Locked
Evercore ISI Group:
Locked
Locked
May 14 2025
Locked
Needham:
Locked
Locked
May 13 2025
Locked
HC Wainwright & Co.:
Locked
Locked
May 13 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today